Thereafter, as TM peptides appear to be effective in specific targeting of dimerization and activation of mNEU1 in vitro, this technique could be used to inhibit in vivo this protein involved in several pathophysiological contexts as atherosclerosis (Gayral et al., 2014; Kawecki et al., 2019), thrombosis (Kawecki et al., 2014), insulin resistance (Blaise et al., 2013), non-alcoholic steatohepatitis (Romier et al., 2018), and cancer (Ntayi et al., 2004; Hornebeck et al., 2005; Pocza et al., 2008; Hou et al., 2016; Ren et al., 2016). The gene discussed is INS; the disease is metabolic dysfunction-associated steatohepatitis.